Adaptive Biotechnologies Corporation (ADPT)
ADPT moved a median of +0.28% 30 minutes after news, and -0.67% by the close. How ADPT actually reacts to news — the realized, point-in-time move the market made, measured across 342 labeled events over the last three years with zero look-ahead.
ADPT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.46% | 60% | 340 |
| 30-min | +0.28% | 54% | 340 |
| 60-min | -0.41% | 45% | 340 |
| to close | -0.67% | 44% | 338 |
| Middle 50% of ADPT reactions | -1.48% to +2.20% |
|---|---|
| Median reaction (30-min) | +0.28% |
| Measured reactions | 342 |
Half of all Adaptive Biotechnologies Corporation news events land between -1.48% and +2.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ADPT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 56 | +0.32% | 63% | +1.35% |
| Price-target raises | 20 | +0.46% | 75% | +1.14% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ADPT ranks against every other measured name →
That’s how ADPT usually reacts — get an email when it moves on news →Email me when ADPT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ADPT's baseline. Nothing else.
Recent ADPT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026 | Press release | GlobeNewswire | -0.94% | +0.43% | |
| Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure | Press release | GlobeNewswire | -0.84% | -1.18% | |
| Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® | Press release | GlobeNewswire | -0.50% | +1.13% | |
| Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | +1.74% | +0.69% | |
| Form 10-Q Adaptive Biotechnologies For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.28% | +0.24% | |
| Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +5.43% | +8.92% | |
| Form 8-K Adaptive Biotechnologies For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | +5.43% | +8.92% | |
| Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 | Press release | GlobeNewswire | +0.20% | -3.92% | |
| Form 8-K Adaptive Biotechnologies For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +1.77% | +0.53% | |
| Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering | Press release | GlobeNewswire | -0.21% | -0.24% | |
| Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses | Press release | GlobeNewswire | +3.64% | +7.09% | |
| Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering | Press release | GlobeNewswire | +3.64% | +7.09% | |
| Form 8-K Adaptive Biotechnologies For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +3.64% | +7.09% | |
| Form 8-K Adaptive Biotechnologies For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +1.87% | -0.47% | |
| At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research | Press release | GlobeNewswire | +0.89% | -0.26% | |
| Adaptive Biotechnologies to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.50% | -0.86% | |
| Adaptive Biotechnologies Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +3.39% | +3.07% | |
| Form 10-Q Adaptive Biotechnologies For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.39% | +3.07% | |
| Form 8-K Adaptive Biotechnologies For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +3.39% | +3.07% | |
| Form ARS Adaptive Biotechnologies For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.46% | +1.28% | |
| Form DEF 14A Adaptive Biotechnologies For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | +0.46% | +1.28% | |
| Form DEFA14A Adaptive Biotechnologies | SEC filing · Form DEFA14A | SEC EDGAR | +0.46% | +1.28% | |
| Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 | Press release | GlobeNewswire | -1.12% | -1.47% | |
| Form S-8 Adaptive Biotechnologies | SEC filing · Form S-8 | SEC EDGAR | +2.35% | +3.93% | |
| Form 10-K Adaptive Biotechnologies For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.43% | -1.29% | |
| Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -6.40% | -11.50% | |
| Form 8-K Adaptive Biotechnologies For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | -6.40% | -11.50% | |
| Adaptive Biotechnologies to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.57% | -3.90% | |
| Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 | Press release | GlobeNewswire | -0.24% | -2.63% | |
| Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results | Press release | GlobeNewswire | +3.48% | +4.28% | |
| Form 8-K Adaptive Biotechnologies For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +3.48% | +4.28% | |
| Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.21% | -1.40% | |
| Form 8-K Adaptive Biotechnologies For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -0.73% | |
| Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer | Press release | GlobeNewswire | -2.97% | -2.12% | |
| Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease | Press release | GlobeNewswire | +0.42% | +5.42% | |
| Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting | Press release | GlobeNewswire | +1.29% | +1.63% | |
| Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting | Press release | GlobeNewswire | -0.63% | +8.03% | |
| Adaptive Biotechnologies to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.82% | -3.40% | |
| Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.89% | -8.20% | |
| Form 10-Q Adaptive Biotechnologies For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.89% | -8.20% | |
| Form 8-K Adaptive Biotechnologies For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | -8.20% | |
| Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025 | Press release | GlobeNewswire | +1.81% | +0.94% | |
| Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference | Press release | GlobeNewswire | +0.38% | +1.99% | |
| Form 8-K Adaptive Biotechnologies For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -1.31% | -4.54% | |
| Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -3.48% | -6.48% | |
| Form 10-Q Adaptive Biotechnologies For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.48% | -6.48% | |
| Form 8-K Adaptive Biotechnologies For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -6.48% | |
| Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 | Press release | GlobeNewswire | +0.00% | -2.69% | |
| Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR® | Press release | GlobeNewswire | -0.48% | -1.84% | |
| Form 8-K Adaptive Biotechnologies For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +2.71% | +3.51% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ADPT section they belong to.
Where else ADPT is measured.
ADPT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Adaptive Biotechnologies Corporation's median reaction calculated?
Every labeled ADPT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 342 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of ADPT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ADPT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.